DE60023845D1 - Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktase - Google Patents

Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktase

Info

Publication number
DE60023845D1
DE60023845D1 DE60023845T DE60023845T DE60023845D1 DE 60023845 D1 DE60023845 D1 DE 60023845D1 DE 60023845 T DE60023845 T DE 60023845T DE 60023845 T DE60023845 T DE 60023845T DE 60023845 D1 DE60023845 D1 DE 60023845D1
Authority
DE
Germany
Prior art keywords
components
antisense sequences
ribonucleotide reductase
sequences against
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023845T
Other languages
English (en)
Other versions
DE60023845T2 (de
Inventor
A Wright
Aiping H Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptose Bioscience Inc
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Publication of DE60023845D1 publication Critical patent/DE60023845D1/de
Application granted granted Critical
Publication of DE60023845T2 publication Critical patent/DE60023845T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
DE60023845T 1999-02-11 2000-02-09 Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktase Expired - Lifetime DE60023845T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/249,730 US6121000A (en) 1999-02-11 1999-02-11 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US249730 1999-02-11
PCT/CA2000/000120 WO2000047733A1 (en) 1999-02-11 2000-02-09 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Publications (2)

Publication Number Publication Date
DE60023845D1 true DE60023845D1 (de) 2005-12-15
DE60023845T2 DE60023845T2 (de) 2006-08-10

Family

ID=22944744

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023845T Expired - Lifetime DE60023845T2 (de) 1999-02-11 2000-02-09 Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktase

Country Status (17)

Country Link
US (1) US6121000A (de)
EP (1) EP1153128B8 (de)
JP (1) JP4424857B2 (de)
KR (1) KR20020013501A (de)
CN (1) CN1345373A (de)
AR (1) AR022583A1 (de)
AT (1) ATE309346T1 (de)
AU (1) AU780455B2 (de)
BR (1) BR0008788A (de)
CA (1) CA2366487A1 (de)
DE (1) DE60023845T2 (de)
ES (1) ES2259602T3 (de)
IL (1) IL144727A0 (de)
MX (1) MXPA01008137A (de)
NZ (1) NZ514090A (de)
RU (1) RU2001124840A (de)
WO (1) WO2000047733A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593305B1 (en) * 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
MXPA04010282A (es) * 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP2006518344A (ja) * 2003-02-10 2006-08-10 ジェネセンス テクノロジーズ インク リボヌクレオチド還元酵素ｒ２を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用
EP1615943A4 (de) * 2003-04-18 2006-08-16 Univ Pennsylvania Zusammensetzung und verfahren for sirna-inhibierung von angiopoietin 1 und 2 und deren rezeptor tie2
CN1302936C (zh) * 2003-05-02 2007-03-07 精工爱普生株式会社 打印机
EP1636363A1 (de) * 2003-05-21 2006-03-22 GeneSense Technologies Inc. Antisense oligonukleotide gegen die ribonukleotid reduktase r1 und deren verwendung für die behandlung von krebs
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005065719A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
CA2564868C (en) * 2004-04-28 2013-11-26 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
WO2007146953A2 (en) * 2006-06-12 2007-12-21 Exegenics, Inc., D/B/A Opko Health, Inc. Compositions and methods for sirna inhibition of angiogenesis
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
EP2030615A3 (de) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
CA2745832A1 (en) 2008-12-04 2010-06-10 Opko Ophthalmics, Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
DE102019000490A1 (de) * 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5766855A (en) * 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (de) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Zelluläre regulation mittelsriboregulatoren
WO1998005769A2 (en) * 1996-08-02 1998-02-12 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Also Published As

Publication number Publication date
WO2000047733A1 (en) 2000-08-17
EP1153128B1 (de) 2005-11-09
RU2001124840A (ru) 2004-03-27
EP1153128A1 (de) 2001-11-14
KR20020013501A (ko) 2002-02-20
ATE309346T1 (de) 2005-11-15
AR022583A1 (es) 2002-09-04
AU780455B2 (en) 2005-03-24
DE60023845T2 (de) 2006-08-10
JP4424857B2 (ja) 2010-03-03
CA2366487A1 (en) 2000-08-17
BR0008788A (pt) 2001-11-06
AU2529200A (en) 2000-08-29
EP1153128B8 (de) 2006-01-18
WO2000047733A9 (en) 2001-03-15
JP2003500006A (ja) 2003-01-07
ES2259602T3 (es) 2006-10-16
US6121000A (en) 2000-09-19
CN1345373A (zh) 2002-04-17
NZ514090A (en) 2005-01-28
IL144727A0 (en) 2002-06-30
MXPA01008137A (es) 2004-08-12

Similar Documents

Publication Publication Date Title
DE60023845D1 (de) Antitumor-antisense sequenzen gegen die r1 und r2 komponenten der ribonukleotidreduktase
ATE450663T1 (de) Verschleissteil und -anordnung
PL370163A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
PT1711470E (pt) Derivados de malonamida que bloqueiam a actividade de gama-secretase
HK1054768B (zh) 阻尼中間柱和使用它的阻尼結構
HUP0600298A3 (en) Reductive cleavage of the exocyclic ester of uk-2a or its derivatives and products formed therefrom
EP1453837A4 (de) Zielgerichtete therapeutika und deren anwendungen
BRPI0208558A2 (pt) preparado de combinação de estrogênio-gestagênio e uso
IL162653A0 (en) Tyrosyl derivatives and their use as p2x7 receptormodulators
DE69903242D1 (de) Sinterkörper hoher Festigkeit
ID30023A (id) Kombinasi senyawa aktif fungisida
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
SI1372652T1 (sl) Kombinacija docetaksela in flavopiridola
ID26881A (id) Bubutan finer
SI1392670T1 (sl) Substituirani C-furan-2-il-metilaminski in C-tiofen-2-il-metilaminski derivati
IL151714A0 (en) Condensation derivatives of thiocolchicine and baccatin as antitumor agents
DE50010258D1 (de) Metallisches Bauteil und Entladungslampe
IL162014A0 (en) Shape-recovering material suitable for application of an attachment, and its use
NO990313D0 (no) Klokke for personer med kognitive problemer
DE29901506U1 (de) Metallbauelement
ATA17852001A (de) Signaturarmer und schadstoffreduzierter, pyrotechnischer darstellungskörper
DE50115118D1 (de) Mikromechanisches bauelement und abgleichverfahren
EP1392460A4 (de) Fluorwasserstoffe von aminosilanolen und ihre verwendung
DE60140770D1 (de) Fixier- und zwischenübertragungsrollen
ES1048676Y (es) Base y cuerpo de andamio de estructura semiporticada.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GENESENSE TECHNOLOGIES, INC., TORONTO, ONTARIO, CA

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LORUS THERAPEUTICS INC., TORONTO, ONTARIO, CA